Seth Pantanelli, MD
Ophthalmology · Hershey, PANPI 1225270226
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $106,698 of the $141,834 with a category attached, or 75.2%. 15 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 56.0% of the total. Reporting peaked in 2024 at $42,949 and has fallen 54.4% since, to $19,601 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $1042.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$79K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$28K
- Carl Zeiss Meditec Cataract Technology Inc.$15K
- Carl Zeiss Meditec USA, Inc.$6K
- Carl Zeiss Meditec Digital Innovations LLC$5K
- Alcon$4K
- plus $4K from 9 others
Across 20 payments — averaging $20,295 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$167K
- Carl Zeiss Meditec Production LLC$88K
- Carl Zeiss Meditec Cataract Technology Inc.$86K
- Ocular Therapeutix, Inc.$35K
- Bausch & Lomb Americas Inc.$30K
What the payments were for
- Consulting fees$106,69875%
- Speaking & faculty fees$21,53015%
- Travel & lodging$3,3482%
- Food & beverage$4,8403%
- Other$5,4184%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 70 | $79,443 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $28,332 |
| Carl Zeiss Meditec Cataract Technology Inc. | 6 | $14,598 |
| Carl Zeiss Meditec USA, Inc. | 22 | $5,565 |
| Carl Zeiss Meditec Digital Innovations LLC | 1 | $5,418 |
| Alcon | 15 | $4,203 |
| Bausch & Lomb Americas Inc. | 6 | $3,659 |
| Hoya Surgical Optics, Inc | 1 | $178 |
| Sun Pharmaceutical Industries Inc. | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 1 | $101 |
| Carl Zeiss Meditec Production LLC | 1 | $69 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $45 |
| Topcon Healthcare, Inc. | 1 | $38 |
| Ivantis, Inc | 1 | $36 |
| Novus Surgical Consultants | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$31,869
- IOLMaster 700$24,996
- VERACITY SURGICAL$23,733
- VisuMax$22,912
- QUATERA 700$18,889
- CLARUS$13,270
- CALLISTO eye$12,244
- VICTUS$10,150
- TORIC$10,000
- Humphrey Field Analyzer (HFA3)$8,273
- ARTEVO 800$7,841
- CT Lucia$7,000
- CIRRUS 6000 with AngioPlex$6,628
- ATLAS 500$5,618
- FORUM Glaucoma Workplace$5,523
- FORUM$5,295
- Retina Workplace$4,873
- IOLMaster$3,625
- MEL 90$3,600
- IOLMaster 500$2,750
How this compares
$141,834 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 29 | $28,139 |
| Prednisolone Acetate | 381 | $15,186 |
| Fluorometholone | 90 | $6,444 |
| Cyclosporine | 11 | $4,184 |
| ValacyclovirValacyclovir Hcl | 66 | $4,089 |
| Loteprednol Etabonate | 24 | $3,292 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $2,808 |
| MoxifloxacinMoxifloxacin Hcl | 44 | $1,524 |
| Brimonidine Tartrate | 27 | $727 |
| ErythromycinErythromycin Base | 41 | $641 |
| Famciclovir | 12 | $551 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 75 | $453 |
| Doxycycline Hyclate | 16 | $445 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $403 |
| Latanoprost | 34 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $28,332 | $3,29224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Hershey
- Ingrid ScottHershey$30K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.